Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion

Abstract Background Most patients with advanced prostate cancer develop bone metastases, which often result in painful and debilitating skeletal-related events. Inhibitors of bone resorption, such as bisphosphonates and denosumab, can each reduce the incidence of skeletal-related events and delay th...

Full description

Bibliographic Details

Published in:	BMC Urology
Main Authors:	Jean-Jacques Body, Roger von Moos, Daniela Niepel, Bertrand Tombal
Format:	Article
Language:	English
Published:	BMC 2018-09-01
Subjects:	Bone-targeted agents Bisphosphonate Denosumab Zoledronic acid Prostate cancer Hypocalcaemia
Online Access:	http://link.springer.com/article/10.1186/s12894-018-0393-9